摘要
目的观察甘糖酯联合依折麦布对冠心病的调脂疗效和安全性。方法选择冠心病伴高脂血症患者共88例,随机分为甘糖酯组44例(给予甘糖酯100mg/次,3次/d),联合治疗组44例(给予甘糖酯片100mg/次,3次/d,依折麦布10mg/d)。观察2组治疗前后血脂水平、药物不良反应等。结果甘糖酯组和联合治疗组治疗8周末与治疗前比较,TC、TG、LDL-C、OX-LDL、CRP水平可见明显下降,HDL-C水平则明显升高,差异有统计学意义(P<0.05)。联合治疗组较甘糖酯组变化更显著,差异有统计学意义(P<0.05)。结论甘糖酯联合依折麦布可以显著降低冠心病伴高脂血症的血脂水平,优于单用甘糖酯,且安全性良好。
Objective To study the influences and safety of mannose ester combining ezetimibe on control-ling the blood lipids in patients with coronary heart disease. Methods 88 CHD patients with hyperlipi-demia were randomly distributed two groups（n=44 in each group）. The mannose ester group were treated with mannose ester orally 100 mg every time, three times a day. The combination group were treated with mannose ester orally 100 mg every time, three times a day and ezetimibe 10 mg/d. Levels of blood lipids before and after the treatment, adverse reactions were observed in two groups. Results On the 8,h week after the treatment, the TC, TG, LDL-C, OX-LDLand CRP levels were lower than those before the treatment in two groups, the HDL-C was higher than that before the treatment in two groups（P〈0. 05）. The changes of the combination group were more significant than those in the man-nose ester group, the difference was statistically significant （P〈0.05）. Conclusions Mannose ester com-bining ezetimibe can significantly reduce the blood lipids in CHD patients with hyperlipidemia, the effect is better than mannose ester only and the safety is good.
出处
《中国海洋药物》
CAS
CSCD
北大核心
2014年第2期74-76,共3页
Chinese Journal of Marine Drugs
关键词
甘糖酯
依折麦布
冠心病
血脂
mannose ester
ezetimibe
coronary heart disease
blood lipids
